Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer

Small GTPases

Volumn 2, Issue 4, 2011, Pages 211-216

  Lacher, Markus D ^a,c   Pincheira, Roxana J ^b   Castro, Ariel F ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

^c BIOTIME INC   (United States)

Author keywords

AMPK; Autophagy; Cancer; LAM; P27; Rheb; TSC

Indexed keywords

CD150 ANTIGEN; HAMARTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROTEIN P27; RHEB PROTEIN; TUBERIN;

ARTICLE; AUTOPHAGY; CARCINOGENESIS; CYTOPLASM; DISEASE COURSE; ENERGY METABOLISM; FEEDBACK SYSTEM; HUMAN; LYMPHANGIOLEIOMYOMATOSIS; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

MAMMALIA;

EID: 80053332722     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.2.4.16703     Document Type: Article

References (46)

1. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010; 21:683-91 PMID:19713247; http://dx.doi.org/10.1093/annonc/mdp347.
2. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008; 412:179-90 PMID:18466115; http://dx.doi.org/10.1042/BJ20080281.
3. Dann SG, Selvaraj A, Thomas G. mTOR Complex1- S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13:252-9 PMID:17452018; http://dx.doi.org/10.1016/j.molmed.2007.04.002.
4. Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003; 278:32493-6 PMID:12842888; http://dx.doi.org/10.1074/jbc.C300226200.
5. Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene 2010; 29:6543-56 PMID:20818424; http://dx.doi.org/10.1038/onc.2010.393.
6. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008; 32:7-12 PMID:18719601; http://dx.doi.org/10.1038/ijo.2008.116.
7. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J 2009; 418:261-75 PMID:19196246; http://dx.doi.org/10.1042/BJ20082055.
8. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283:10892-903 PMID:18281291; http://dx.doi.org/10.1074/jbc.M800102200.
9. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004; 428:569-74 PMID:15058305; http://dx.doi.org/10.1038/nature02440.
10. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010; 9:1092-9 PMID:20442309; http://dx.doi.org/10.1158/1535-7163.MCT-09-1186.
11. Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, et al. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 2008; 68:6496-506 PMID:18701472; http://dx.doi.org/10.1158/0008-5472.CAN-07-5756.
12. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8:733-41 PMID:19372545; http://dx.doi.org/10.1158/1535-7163.MCT-08-0631.
13. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9:218-24 PMID:17237771; http://dx.doi.org/10.1038/ncb1537.
14. Kip1 metabolism: a fascinating labyrinth. Cell Cycle 2007; 6:1053-61 PMID:17426451; http://dx.doi.org/10.4161/cc.6.9.4142.
15. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8:253-67 PMID:18354415; http://dx.doi.org/10.1038/nrc2347.
16. KIP1 during tumor development. Exp Mol Med 2009; 41:765-71 PMID:19887899; http://dx.doi.org/10.3858/emm.2009.41.11.102.
17. Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21:1731-46 PMID:17626791; http://dx.doi.org/10.1101/gad.1556607.
18. Short JD, Dere R, Houston KD, Cai SL, Kim J, Bergeron JM, et al. AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 2010; 49:429-39 PMID:20146253.
19. Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Lett 2010; 584:1427-35 PMID:20035753; http://dx.doi.org/10.1016/j.febslet.2009.12.034.
20. Rosenfeldt MT, Ryan KM. The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med 2009; 11:36 PMID:19951459; http://dx.doi.org/10.1017/S1462399409001306.
21. Mathew R, Kongara S, Beaudoin B, Karp CM, Bray K, Degenhardt K, et al. Autophagy suppresses tumor pro gression by limiting chromosomal instability. Genes Dev 2007; 21:1367-81 PMID:17510285; http://dx.doi.org/10.1101/gad.1545107.
22. Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007; 21:1621-35 PMID:17606641; http://dx.doi.org/10.1101/gad.1565707.
23. Yen WL, Klionsky DJ. How to live long and prosper: autophagy, mitochondria and aging. Physiology (Bethesda) 2008; 23:248-62 PMID:18927201; http://dx.doi.org/10.1152/physiol.00013.2008.
24. White E. Role of the metabolic stress responses of apoptosis and autophagy in tumor suppression. Ernst Schering Found Symp Proc 2007; 23-34.
25. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 2010; 22:177-80 PMID:20022734; http://dx.doi.org/10.1016/j.ceb.2009.11.015.
26. Papandreou I, Lim AL, Laderoute K, Denko NC. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3 and BNIP3L. Cell Death Differ 2008; 15:1572-81; PMID:18551130; http://dx.doi.org/10.1038/cdd.2008.84.
27. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33 PMID:19460998; http://dx.doi.org/10.1126/science.1160809.
28. Schneider A, Younis RH, Gutkind JS. Hypoxiainduced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 2008; 10:1295-302 PMID:18953439.
29. Emerling BM, Weinberg F, Snyder C, Burgess Z, Mutlu GM, Viollet B, et al. Hypoxic activation of AMPK is dependent on mitochondrial ROS but independent of an increase in AMP/ ATP ratio. Free Radic Biol Med 2009; 46:1386-91 PMID:19268526; http://dx.doi.org/10.1016/j.freeradbiomed.2009.02.019.
30. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009; 20:1981-91 PMID:19211835; http://dx.doi.org/10.1091/mbc.E08-12-1248.
31. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30:214-26 PMID:18439900; http://dx.doi.org/10.1016/j.molcel.2008.03.003.
32. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011; 13:132-41 PMID:21258367; http://dx.doi.org/10.1038/ncb2152.
33. Löffler AS, Alers S, Dieterle AM, Keppeler H, Franz-Wachtel M, Kundu M, et al. Ulk1-mediated phosphorylation of AMPK constitutes a negative regulatory feedback loop. Autophagy 2011; 7:696-706 PMID:21460634.
34. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001; 264:148-68 PMID:11237531; http://dx.doi.org/10.1006/excr.2000.5143.
35. Kang YJ, Lu MK, Guan KL. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stressinduced apoptosis. Cell Death Differ 2011; 18:133-44 PMID:20616807; http://dx.doi.org/10.1038/cdd.2010.82.
36. Ermoian RP, Kaprealian T, Lamborn KR, Yang X, Jelluma N, Arvold ND, et al. Signal transduction molecules in gliomas of all grades. J Neurooncol 2009; 91:19-26 PMID:18759130; http://dx.doi.org/10.1007/s11060-008-9683-5.
37. Knowles MA, Hornigold N, Pitt E. Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Trans 2003; 31:597-602 PMID:12773163; http://dx.doi.org/10.1042/BST0310597.
38. Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A. Involvement of TSC genes and differentialexpression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer 2008; 8:163 PMID:18538015; http://dx.doi.org/10.1186/1471-2407-8-163.
39. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005; 41:1628-36 PMID:15951164; http://dx.doi.org/10.1016/j.ejca.2005.03.023.
40. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, et al. Loss of tuberous sclerosis complex- 2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2008; 14:2543-50.
41. Winter JN, Jefferson LS, Kimball SR. ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling. Am J Physiol Cell Physiol 2011; 300:1172-80 PMID:21289294;http://dx.doi.org/10.1152/ajpcell.00504.2010.
42. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126:955-68 PMID:16959574; http://dx.doi.org/10.1016/j.cell.2006.06.055.
43. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574:63-71 PMID:16613876; http://dx.doi.org/10.1113/jphysiol.2006.108324.
44. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006; 25:6436-46 PMID:17041628; http://dx.doi.org/10.1038/sj.onc.1209886.
45. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010; 67:2095-106 PMID:21116000; http://dx.doi.org/10.2146/ajhp100020.
46. Paul E, Thiele E. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis. N Engl J Med 2008; 358:190-2 PMID:18184966; http://dx.doi.org/10.1056/NEJMe0707153.